Skip to Content
Stock Strategist Industry Reports

Health Insurer Review Results in Higher Valuations

Our Anthem and Humana fair value estimates get a boost.

Mentioned: , , , ,

We have completed our review of the U.S. health insurance industry and have a fresh take on Anthem (ANTM) and Humana (HUM). After the review, we raised our fair value estimates for both companies to reflect higher cash flow assumptions and recently generated cash flow since our last update. We are reiterating our narrow economic moat and stable trend ratings for Anthem and Humana, putting them in line with the rest of their managed-care peers.

Our narrow-moat view of the industry is informed by an analysis of potential changes to the U.S. healthcare system. Polling suggests that about half of the U.S. population is supportive of a “Medicare for All” scenario. In a Medicare for All scenario where U.S. insurers have no place in the U.S. insurance market, private insurers’ operations could be in jeopardy. However, we believe this scenario represents a very low-probability risk (5% or less) within our 10-year forecast period, as it would require significant shifts in current federal government control, including a filibuster-proof Democratic majority position in the Senate and a new president from the left wing of the Democratic Party, as Republican voters remain significantly opposed to such a plan.

Julie Utterback does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.